TARA vs. AVBP, ORGO, CVAC, GHRS, NUVB, CRMD, IMNM, ABUS, BCYC, and DNTH
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include ArriVent BioPharma (AVBP), Organogenesis (ORGO), CureVac (CVAC), GH Research (GHRS), Nuvation Bio (NUVB), CorMedix (CRMD), Immunome (IMNM), Arbutus Biopharma (ABUS), Bicycle Therapeutics (BCYC), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry.
Protara Therapeutics vs.
Protara Therapeutics (NASDAQ:TARA) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Protara Therapeutics received 18 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 68.42% of users gave Protara Therapeutics an outperform vote.
In the previous week, Protara Therapeutics had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 5 mentions for Protara Therapeutics and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.92 beat Protara Therapeutics' score of 0.70 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
ArriVent BioPharma is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Protara Therapeutics currently has a consensus target price of $22.50, suggesting a potential upside of 460.40%. ArriVent BioPharma has a consensus target price of $39.00, suggesting a potential upside of 145.75%. Given Protara Therapeutics' higher possible upside, equities analysts clearly believe Protara Therapeutics is more favorable than ArriVent BioPharma.
ArriVent BioPharma's return on equity of -43.89% beat Protara Therapeutics' return on equity.
38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 12.5% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Protara Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
Summary
Protara Therapeutics beats ArriVent BioPharma on 9 of the 15 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TARA) was last updated on 4/4/2025 by MarketBeat.com Staff
Buy TARA Stock Free TARA Stock Alerts